Day: September 24, 2019

Aytu BioScience Announces Addition of Natesto(R) to Leading National Pharmacy Benefit Manager’s Formulary; Natesto Added to Commercial Plans Covering Over 30 Million U.S. Lives

During the 12-month period ending June 2019, the U.S. prescription TRT market registered 6.9 million prescriptions, generating approximately $1.7 billion...

Jaguar Health to Host Investor Call October 3rd at 8 a.m. Eastern to Provide Updates Regarding Development of Mytesi for the Potential Follow-on Indication of Cancer Therapy-Related Diarrhea

AIM ImmunoTech Inc. Announces a Second DoD Award, This One of $8.3 Million, to Fund Phase 2 Clinical Trial to Study Ampligen as Part of a New Treatment for Brain-Metastatic Breast Cancer at the Moffitt Cancer Center

error: Content is protected !!